Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$15.9b

Neurocrine Biosciences Future Growth

Future criteria checks 5/6

Neurocrine Biosciences is forecast to grow earnings and revenue by 24% and 12% per annum respectively. EPS is expected to grow by 22.2% per annum. Return on equity is forecast to be 21.3% in 3 years.

Key information

24.0%

Earnings growth rate

22.18%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate12.0%
Future return on equity21.32%
Analyst coverage

Good

Last updated29 May 2026

Recent future growth updates

Analysis Article • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...

Recent updates

Narrative Update • May 26

NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns

Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.
Analysis Article • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...
Narrative Update • May 07

NBIX: Future Upside Will Depend On Execution Across Two Core Franchises

The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.
Seeking Alpha • May 06

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Summary Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance. My fair value estimate for NBIX rises to just under $206/share, supported by multiyear upside in Ingrezza, Crenessity, and a promising, though long-dated, pipeline. I maintain a bullish stance on NBIX, seeing the market undervaluing core franchises and risk-adjusted pipeline upside despite tempered guidance. Read the full article on Seeking Alpha
Narrative Update • Apr 21

NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution

The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.
Narrative Update • Apr 07

NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns

Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.
Narrative Update • Mar 24

NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress

Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.
Narrative Update • Mar 09

NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns

Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.
Narrative Update • Feb 23

NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook

Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.
Narrative Update • Feb 09

NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery

Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.
Narrative Update • Jan 24

NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises

Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.
Narrative Update • Jan 10

NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns

Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.
Narrative Update • Dec 17

NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns

Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.
Narrative Update • Dec 03

NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value

Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.
Narrative Update • Nov 19

NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds

Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.
Narrative Update • Nov 05

NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value

The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.
Narrative Update • Oct 22

Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results

Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.
Seeking Alpha • Apr 22

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Summary Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity. NBIX stock's valuation compared to peers suggests the recent market reaction may be overdone, positioning it as a potential takeover target with a valuation closer to $15 billion, in my view. Read the full article on Seeking Alpha
New Narrative • Mar 20

Neurocrine Biosciences revenue will grow by 10% with Crenessity and Ingrezza sales if they can maintain the retail price.

Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Earnings and Revenue Growth Forecasts

NasdaqGS:NBIX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20285,0551,4411,7571,81714
12/31/20274,5161,1211,4051,41818
12/31/20263,76950293771819
3/31/20263,102669831864N/A
12/31/20252,861479749783N/A
9/30/20252,683428593637N/A
6/30/20252,510348529567N/A
3/31/20252,413306492530N/A
12/31/20242,355341557595N/A
9/30/20242,243386440476N/A
6/30/20242,120339495530N/A
3/31/20241,982370614645N/A
12/31/20231,887250362390N/A
9/30/20231,784191385409N/A
6/30/20231,673176281296N/A
3/31/20231,59964237255N/A
12/31/20221,489155323339N/A
9/30/20221,38958177201N/A
6/30/20221,29712133164N/A
3/31/20221,20871102129N/A
12/31/20211,13490233257N/A
9/30/20211,069445328347N/A
6/30/20211,032365251265N/A
3/31/20211,045402266280N/A
12/31/20201,046407218229N/A
9/30/20201,04293222232N/A
6/30/20201,006205337350N/A
3/31/2020887177283295N/A
12/31/201978837N/A147N/A
9/30/201967521N/A100N/A
6/30/201960518N/A71N/A
3/31/2019519-39N/A27N/A
12/31/201845121N/A101N/A
9/30/201841410N/A91N/A
6/30/2018323-52N/A13N/A
3/31/2018233-106N/A-55N/A
12/31/2017162-143N/A-94N/A
9/30/201767-194N/A-167N/A
6/30/20176-220N/A-188N/A
3/31/2017N/A-200N/A-154N/A
12/31/201615-141N/A-106N/A
9/30/201615-126N/A-90N/A
6/30/201615-123N/A-77N/A
3/31/201615-107N/A-49N/A
12/31/201520-89N/A-38N/A
9/30/201520-79N/A-38N/A
6/30/201520-60N/A-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NBIX's forecast earnings growth (24% per year) is above the savings rate (3.5%).

Earnings vs Market: NBIX's earnings (24% per year) are forecast to grow faster than the US market (17% per year).

High Growth Earnings: NBIX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NBIX's revenue (12% per year) is forecast to grow faster than the US market (11.9% per year).

High Growth Revenue: NBIX's revenue (12% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (21.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/30 18:46
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurocrine Biosciences, Inc. is covered by 40 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martha FreitagArgus Research Company
Brian SkorneyBaird
Aydin HuseynovBenchmark Company